Paper41249657
Improving surgical treatments for hepatocellular carcinoma.
Malik AK and 5 others. Nat Rev Gastroenterol Hepatol, 2026. Cited by 14 papers, by iCite.
Cite this record
ConductScience Library. Improving surgical treatments for hepatocellular carcinoma. Papers, record 41249657. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41249657
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| Humans | |
| Neoplasm Recurrence, Local | |
| Hepatectomy | |
| Liver Transplantation | |
| Neoadjuvant Therapy | |
| Immunotherapy | |
| Precision Medicine |
Source PubMed
References248
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28299619 | Double- and Triple-Positive Tumor Markers Predict Early Recurrence and Poor Survival in Patients with Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh Class A. | J Gastrointest Surg | 2017 | https://conductscience.org/library/papers/28299619 | PubMed |
| 2 | 36810207 | Cost of hepatocellular carcinoma to the national health service in England: a registry-based analysis. | BMJ Open Gastroenterol | 2023 | https://conductscience.org/library/papers/36810207 | PubMed |
| 3 | 37683735 | AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation. | J Hepatol | 2023 | https://conductscience.org/library/papers/37683735 | PubMed |
| 4 | 31550417 | Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient? | Am J Transplant | 2020 | https://conductscience.org/library/papers/31550417 | PubMed |
| 5 | 39255928 | Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: The multicenter VITALITY study. | J Hepatol | 2025 | https://conductscience.org/library/papers/39255928 | PubMed |
| 6 | 35258511 | Liver Transplantation Outcomes From Controlled Circulatory Death Donors: SCS vs in situ NRP vs ex situ NMP. | Ann Surg | 2022 | https://conductscience.org/library/papers/35258511 | PubMed |
| 7 | 18650514 | Sorafenib in advanced hepatocellular carcinoma. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18650514 | PubMed |
| 8 | 37208105 | Machine perfusion of the liver and bioengineering. | J Hepatol | 2023 | https://conductscience.org/library/papers/37208105 | PubMed |
| 9 | 28371119 | Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2-independent mechanism. | Aging Cell | 2017 | https://conductscience.org/library/papers/28371119 | PubMed |
| 10 | 29798856 | Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. | Science | 2018 | https://conductscience.org/library/papers/29798856 | PubMed |
| 11 | 36450386 | Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study. | J Immunother Cancer | 2022 | https://conductscience.org/library/papers/36450386 | PubMed |
| 12 | 28473688 | Long-Term Outcome of Liver Resection Versus Transplantation for Hepatocellular Carcinoma in a Region Where Living Donation is a Main Source. | Ann Transplant | 2017 | https://conductscience.org/library/papers/28473688 | PubMed |
| 13 | 32695968 | New frontiers in liver resection for hepatocellular carcinoma. | JHEP Rep | 2020 | https://conductscience.org/library/papers/32695968 | PubMed |
| 14 | 36470717 | Application of hazard functions to investigate recurrence after curative-intent resection for hepatocellular carcinoma. | HPB (Oxford) | 2023 | https://conductscience.org/library/papers/36470717 | PubMed |
| 15 | 23108125 | Resection or transplantation for early hepatocellular carcinoma in a cirrhotic liver: does size define the best oncological strategy? | Ann Surg | 2012 | https://conductscience.org/library/papers/23108125 | PubMed |
| 16 | 33800224 | Influence of Hepatocellular Carcinoma on Platelet Aggregation in Cirrhosis. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33800224 | PubMed |
| 17 | 35120736 | Baveno VII - Renewing consensus in portal hypertension. | J Hepatol | 2022 | https://conductscience.org/library/papers/35120736 | PubMed |
| 18 | 36124430 | mTORi-based immunosuppression reduces HCC recurrence at the expense of increased adverse side effects: A systematic review and meta-analysis. | Clin Transplant | 2022 | https://conductscience.org/library/papers/36124430 | PubMed |
| 19 | 37351126 | Resection vs. transplantation for hepatocellular carcinoma: a never ending challenge. | Hepatobiliary Surg Nutr | 2023 | https://conductscience.org/library/papers/37351126 | PubMed |
| 20 | 10094953 | Preoperative portal vein embolization: an audit of 84 patients. | Hepatology | 1999 | https://conductscience.org/library/papers/10094953 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42840030 | An inflammation-nutrition-surgery-based INSEP model and a web-based clinical decision support system for predicting early postoperative infection in elderly patients with hepatocellular carcinoma: a multicenter retrospective study. | Front Nutr | 2026 | https://conductscience.org/library/papers/42840030 | PubMed |
| 42767769 | NKG2A-HLA-E axis contributes to an immunosuppressive checkpoint network in hepatocellular carcinoma. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/42767769 | PubMed |
| 42709244 | Effects of inhaled lavender essential oil on sleep quality, pain, and anxiety in ICU patients after curative hepatocellular carcinoma resection: a quasi-experimental study. | Support Care Cancer | 2026 | https://conductscience.org/library/papers/42709244 | PubMed |
| 42683256 | Mac-2 Binding Protein Glycosylation Isomer (M2BPGi)-Based Risk Stratification Refined by Tumor Metabolic Activity in Hepatocellular Carcinoma. | Ann Gastroenterol Surg | 2026 | https://conductscience.org/library/papers/42683256 | PubMed |
| 42581040 | Temperature-sensitive liquid embolic agent transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for BCLC Stage B/C hepatocellular carcinoma: a multicenter real-world study and spatial transcriptomics profiling (CHANCE 2515). | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42581040 | PubMed |
| 42548727 | Integrative Multiomics Analysis Reveals a Cancer Stem Cell-Driven Prognostic Signature and Nominates Belinostat for Targeted Therapy in Hepatocellular Carcinoma. | Stem Cells Int | 2026 | https://conductscience.org/library/papers/42548727 | PubMed |
| 42404398 | Development and Validation of a Six-Gene Signature of Myeloid Antigen Presentation Dysfunction Based on Single-Cell and Multi-Cohort Transcriptomics for Predicting Prognosis and Recurrence of Hepatocellular Carcinoma. | Cancer Inform | 2026 | https://conductscience.org/library/papers/42404398 | PubMed |
| 42404106 | Emerging Role of Sirtuins-Mediated Ferroptosis in Hepatocellular Carcinoma Progression: Mechanisms and Therapeutic Perspectives. | J Hepatocell Carcinoma | 2026 | https://conductscience.org/library/papers/42404106 | PubMed |
| 42365459 | Independent Prognosis Prediction of Hepatocellular Carcinoma Using MicroRNA-Based Single and Combined Biomarkers. | Can J Gastroenterol Hepatol | 2026 | https://conductscience.org/library/papers/42365459 | PubMed |
| 42005557 | Global Advances in Hepatocellular Carcinoma Research and Therapy in 2025. | Cancer Innov | 2026 | https://conductscience.org/library/papers/42005557 | PubMed |
| 41953857 | Understanding Liver and Digestive Diseases: A Paved Road to Improve Diagnosis, Management, and Treatment. | Explor Dig Dis | 2026 | https://conductscience.org/library/papers/41953857 | PubMed |
| 41913379 | Surgery-centered integrated strategies for personalized hepatocellular carcinoma care. | Cancer Biol Med | 2026 | https://conductscience.org/library/papers/41913379 | PubMed |
| 41873435 | Construction and Validation of a Predictive Model for Post-TACE Recurrence Risk in Hepatocellular Carcinoma: A Retrospective Cohort Study. | J Hepatocell Carcinoma | 2026 | https://conductscience.org/library/papers/41873435 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41249657
GET https://conductscience.org/api/papers/v1/41249657/references?page=2